The landmark judgment of the Supreme Court of India in Novartis AG & Ors. .v. Union of India & Ors. AIR 2013 SC 1311, a case that dealt with the patenting of a polymorphic form of the anti-cancer drug Imatinib mesylate, created a furor at the international level, particularly within the pharmaceutical and drug discovery communities. This fear and confusion have only been exacerbated by subsequent decisions by Indian courts rejecting patents for a series of pharmaceutical substances. Most of these decisions centered on section 3(d) of the Indian Patent Act, which was introduced in 2005. In the midst of these controversies, it has gone unnoticed that patented drugs are becoming more common at the commercial level in India. The country is slowly moving to an exclusive patent regime for new drug substances similar to that of major markets like the United States and Europe. Recognition of this trend has been obfuscated by the controversy over section 3(d).
Proper Interpretation of Section 3(d) of the Indian Patent Act Could Save Incremental Innovations of Existing Pharmaceutical Substances
No Comments
Litigation
- Ericsson Wins Anti-Interference Injunction Against Samsung in Texas FRAND Case
- Supreme Court Will Review Doctrine of Assignor Estoppel
- Patent Filings Roundup: IP Edge End-of-Year Filing Spree, WSOU Ends Year as Top Single-Entity Filer; AC Competitors Go to War Over a Cool Million
- Alice in 2020: Slashing Software Patents and Searching for Functional Language at the Federal Circuit (Part I)
- Inventors Have Their Say on PTAB at SCOTUS in Arthrex Amicus Briefs
Recent Posts
- Biden’s Opportunity to Protect American Innovation
- Washington Insiders Say Farewell to 2020 and Look Ahead to 2021
- Innovation Alliance Urges Biden Administration to Support Patent Rights
- From Agent to Examiner and Back Again: Practical Lessons Learned from Inside the USPTO
- Other Barks & Bites for Friday, January 15: Copyright Office Issues Final Rule on Unmatched Musical Works Under MMA, $1 Billion Copyright Verdict Against Cox Communications Upheld, USPTO Publishes Report on China IP Filings